Fermenta Biotech files BRSR for FY 2025-26
Fermenta Biotech filed its BRSR for FY 2025-26, revealing exports made up 58% of turnover. The company employs 891 people and reported a paid-up capital of ₹14,71,54,935.
*this image is generated using AI for illustrative purposes only.
Fermenta Biotech has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to BSE Limited. The disclosure forms part of the company's Annual Report 2025-26 and outlines its adherence to the National Guidelines for Responsible Business Conduct issued by the Ministry of Corporate Affairs. The report highlights that exports accounted for 58% of the company's total turnover in FY 2025-26.
The company operates four plants and one office nationally, serving approximately 20 states and exporting to around 60 countries. Its primary business activities include the manufacturing of Active Pharmaceutical Ingredients, Aqua CHL, Biotechnology, and Nutraceutical products, which constituted 96.4% of the entity's turnover. Vitamin D3 products were the largest contributor, accounting for 87% of the total turnover.
Employee and Workforce Statistics
As of March 31, 2026, Fermenta Biotech employed a total of 891 individuals, comprising 563 employees and 328 workers. The workforce included 535 permanent employees and 95 permanent workers. Women represented 7.28% of the total employee strength and 1.83% of the total worker strength. The company reported that one differently-abled employee was on its rolls.
The Board of Directors comprised nine members, with three women directors representing 33.33% of the board. Key Management Personnel included six members, with one woman holding the position of Executive Director.
Financial and Operational Metrics
The report disclosed a paid-up capital of ₹14,71,54,935. For Corporate Social Responsibility (CSR) purposes, the company reported a turnover of ₹43,053.17 Lakhs and a net worth of ₹37,995.23 Lakhs for the standalone financial year 2024-25. The company confirmed that CSR is applicable under section 135 of the Companies Act, 2013.
| Metric | Value |
|---|---|
| Paid-up Capital | ₹14,71,54,935 |
| CSR Turnover (Standalone FY 2024-25) | ₹43,053.17 Lakhs |
| CSR Net Worth (Standalone FY 2024-25) | ₹37,995.23 Lakhs |
| Export Contribution to Turnover (FY 2025-26) | 58% |
Governance and Compliance
The company stated that all policies required by statute have been approved by the Board of Directors. Principle 7 of the National Guidelines on Responsible Business Conduct, regarding influencing public and regulatory policy, was marked as not applicable to the company. Fermenta Biotech holds various certifications including EU-GMP, USFDA, WHO-GMP, ISO 9001, ISO 14001, and ISO 45001.
Regarding grievances, the company reported three complaints from shareholders and 12 from customers in FY 2025-26, all of which were resolved. No complaints were pending resolution at the close of the year. The company also disclosed receiving a GST demand order amounting to ₹1,35,64,986, against which it has preferred an appeal and paid a pre-deposit of ₹13,56,500.
Historical Stock Returns for Fermenta Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.86% | -2.11% | +27.16% | +36.82% | +36.82% | +36.82% |
How will the company address the low gender diversity within its workforce compared to its board representation?
What strategies are being implemented to diversify revenue beyond Vitamin D3, which currently accounts for 87% of turnover?
What is the expected timeline and financial impact of the resolution regarding the pending GST demand appeal?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
